Valeant to sell iNova unit for $930M

Valeant Pharmaceuticals International Inc. reached a deal to sell its iNova Pharmaceuticals unit for $930 million.

The buyer is a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group.

Valeant's iNova sells prescription and over-the-counter products for weight and pain managements, cardiology, and cough and cold.

Read more from The Wall Street Journal.